Monday September 23, 2019

Optimism May Lower Diabetes Risk in Postmenopausal Women: Study

The prevalence of diabetes increases with age, with a 25.2 per cent prevalence in those aged 65 years or older

0
//
Pregnancy
The study included 4,697 mothers and 4,832 children. (IANS)

While it is known that a positive personality can help one succeed in life, a new study suggests that traits such as optimism may actually help reduce the risk of developing Type-2 diabetes.

The study examined whether personality traits, including optimism, negativity, and hostility, were associated with the risk of developing Type-2 diabetes in postmenopausal women.

Depression and cynicism were found to be associated with an increased risk of diabetes.

In addition, high levels of hostility were associated with high fasting glucose levels, insulin resistance, and prevalent diabetes.

For the study, published in the journal Menopause, researchers followed 139,924 postmenopausal women amongst which 19,240 cases of Type-2 diabetes were identified.

Diabetes
Representational image. Pixabay

Compared with women who were least optimistic, women who were the most optimistic had a 12 per cent lower risk of incident diabetes, results showed.

In addition, the association of hostility with the risk of diabetes was stronger in women who were not obese compared with women who were.

Hence, low optimism, high negativity and hostility were associated with increased risk of incident diabetes in postmenopausal women, independent of major health behaviours and depressive symptoms, the study concluded.

Also Read- It is Now Possible to Reverse Memory Loss Caused by Alzheimer’s, Says Study

“In addition to using personality traits to help us identify women at higher risk for developing diabetes, more individualised education and treatment strategies should also be used,” said Joann Pinkerton, executive director at The North American Menopause Society.

The prevalence of diabetes increases with age, with a 25.2 per cent prevalence in those aged 65 years or older. (IANS)

Next Story

Diabetes Medication to Reduce Heart Disease Shows Promise: Researchers

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period

0
diabetes
Diabetes is the ninth leading cause of death in women and claims 2.1 million female lives every year, more so than men. Pixabay

Researchers, including one of an Indian-origin, have shed light on how a class of medications that help regulate blood sugar for patients with Type 2 diabetes can also protect from heart disease.

The findings published in the journal Cell Metabolism, focus on the effect of diabetes medication — empagliflozin — on cell repair in blood vessels and the resulting risks of heart disease.

Empagliflozin is a medication that falls under a category of drugs called SGLT2 inhibitors, which lower blood sugar.

“We have seen large-scale clinical trials giving us clear evidence that SGLT2 inhibitors can also protect our patients who have diabetes from heart disease,” said Indian-origin researcher and study author Subodh Verma from St. Michael’s Hospital in Canada.

The research suggests that circulating progenitor cells — which are found in the bone marrow and play a role in heart health — along with inflammatory cells are regulated with this diabetes medication.

For patients who have diabetes are at the risk of heart disease, such medications may provide heart protection by relieving damaged cells that would otherwise perpetuate heart disease by causing faulty vessel repair.

Diabetes
According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes. Pixabay

Using blood samples from the EMPA-HEART CardioLink-6 Trial, the research team was able to show that in diabetes, regenerative progenitor cells were reduced.

Patients who took empagliflozin, however, these progenitor cells were restored later.

“We found that in people with diabetes, not only were beneficial progenitor cells increased but we saw indications of reduced inflammation and oxidative stress, which can also contribute to cardiovascular disease,” said David Hess, Associate Professor at Western University.

According to the researchers, these novel findings may provide the basis for new therapies for patients who have heart disease complicated by diabetes.

Also Read: Social Networking Giant Facebook Plans Test to Let Users Hide ‘Like’ Counts

Earlier a research from Karolinska Institute in Sweden said that the new type of drugs for type 2 diabetes — SGLT2 inhibitors — are associated with a reduced risk of heart failure by 34 per cent.

The results are applicable primarily to dapagliflozin, which was the predominant SGLT2 inhibitor used in Scandinavia during the study period. (IANS)